$625 Million is the total value of Aisling Capital Management LP's 21 reported holdings in Q2 2021. The portfolio turnover from Q1 2021 to Q2 2021 was 40.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BBIO | BridgeBio Pharma Inc. (BBIO) | $369,913,000 | -1.0% | 6,068,125 | 0.0% | 59.23% | -12.0% | |
| ELEV | New | Elevation Oncology Inc. (ELEV) | $38,470,000 | – | 2,834,910 | +100.0% | 6.16% | – |
| GLUE | New | Monte Rosa Therapeutics Inc. (GLUE) | $33,422,000 | – | 1,472,331 | +100.0% | 5.35% | – |
| HRMY | Harmony Biosciences Holdings Inc. (HRMY) | $23,793,000 | -14.6% | 842,815 | 0.0% | 3.81% | -24.0% | |
| NUVB | Nuvation Bio Inc. (NUVB) | $23,657,000 | -10.9% | 2,541,009 | 0.0% | 3.79% | -20.7% | |
| SNDX | Syndax Pharmaceuticals, Inc. (SNDX) | $17,599,000 | -23.2% | 1,025,000 | 0.0% | 2.82% | -31.7% | |
| SPRB | Spruce Biosciences, Inc. (SPRB) | $13,514,000 | -32.5% | 1,205,511 | 0.0% | 2.16% | -39.9% | |
| BMEA | New | Biomea Fusion Inc. (BMEA) | $12,469,000 | – | 798,757 | +100.0% | 2.00% | – |
| AGLE | Aeglea Biotherapeutics Inc. (AGLE) | $11,770,000 | -12.1% | 1,691,151 | 0.0% | 1.88% | -21.9% | |
| ACRS | Aclaris Theraputics Inc. (ACRS) | $11,141,000 | -30.3% | 634,455 | 0.0% | 1.78% | -38.0% | |
| PSTX | Poseida Therapeutics Inc. (PSTX) | $10,454,000 | +4.9% | 1,043,267 | 0.0% | 1.67% | -6.6% | |
| TALS | New | Talaris Therapeutics Inc. (TALS) | $10,032,000 | – | 682,923 | +100.0% | 1.61% | – |
| AVRO | AVROBIO, Inc. (AVRO) | $8,977,000 | -29.9% | 1,009,779 | 0.0% | 1.44% | -37.7% | |
| MRKR | Marker Therapeutics, Inc. (MRKR) | $8,769,000 | +24.6% | 3,142,857 | 0.0% | 1.40% | +10.8% | |
| VRNA | Verona Pharma plc (VRNA)sponsored ads | $8,714,000 | -21.8% | 1,332,485 | 0.0% | 1.40% | -30.4% | |
| RPHM | New | Reneo Pharmaceuticals Inc. (RPHM) | $8,267,000 | – | 886,075 | +100.0% | 1.32% | – |
| OBSV | ObsEva SA (OBSV) | $4,201,000 | -6.8% | 1,386,338 | 0.0% | 0.67% | -17.0% | |
| BCEL | Atreca Inc. (BCEL) | $3,303,000 | -44.4% | 387,653 | 0.0% | 0.53% | -50.6% | |
| VIRX | New | Viracta Therapeutics Inc. (VIRX) | $3,272,000 | – | 288,571 | +100.0% | 0.52% | – |
| ZSAN | Zosano Pharma Corporation (ZSAN) | $2,583,000 | -23.4% | 2,718,226 | 0.0% | 0.41% | -31.8% | |
| Nabriva Therapeutics plc (NBRV) | $258,000 | -18.6% | 191,028 | 0.0% | 0.04% | -28.1% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-08-06
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Verona Pharma plc (VRNA) | 20 | Q3 2023 | 23.0% |
| AVROBIO, Inc. (AVRO) | 20 | Q3 2023 | 13.6% |
| Aclaris Theraputics Inc. (ACRS) | 20 | Q3 2023 | 6.6% |
| Aeglea Biotherapeutics Inc. (AGLE) | 19 | Q2 2023 | 7.5% |
| BridgeBio Pharma Inc. (BBIO) | 18 | Q3 2023 | 67.3% |
| Marker Therapeutics, Inc. (MRKR) | 18 | Q1 2023 | 11.7% |
| Atreca Inc. (BCEL) | 18 | Q3 2023 | 3.1% |
| Syndax Pharmaceuticals, Inc. (SNDX) | 15 | Q3 2023 | 17.2% |
| Zosano Pharma Corporation (ZSAN) | 15 | Q2 2022 | 5.8% |
| ObsEva SA (OBSV) | 14 | Q1 2022 | 18.5% |
View Aisling Capital Management LP's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-07 |
| 13F-HR | 2023-11-13 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-09 |
| 13F-HR | 2023-02-09 |
| 13F-HR | 2022-11-03 |
| 13F-HR | 2022-08-10 |
| 13F-HR | 2022-05-10 |
| 13F-HR | 2022-02-18 |
| 13F-HR | 2021-11-12 |
View Aisling Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.